Provided by Tiger Fintech (Singapore) Pte. Ltd.

AbbVie

193.27
-1.8300-0.94%
Volume:795.71K
Turnover:152.67M
Market Cap:341.89B
PE:82.60
High:193.57
Open:192.73
Low:189.80
Close:195.10
Loading ...

High Growth Tech Stocks In The US Market April 2025

Simply Wall St.
·
Yesterday

Moderna (MRNA) Reports Earnings Tomorrow: What To Expect

StockStory
·
Yesterday

Amgen (AMGN) Reports Earnings Tomorrow: What To Expect

StockStory
·
Yesterday

Biogen Earnings: What To Look For From BIIB

StockStory
·
Yesterday

What To Expect From BioMarin Pharmaceutical’s (BMRN) Q1 Earnings

StockStory
·
Yesterday

BRIEF-RINVOQ (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA)

Reuters
·
29 Apr

Guggenheim Adjusts AbbVie Price Target to $216 From $214, Maintains Buy Rating

MT Newswires Live
·
29 Apr

Rinvoq® (Upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (Gca)

THOMSON REUTERS
·
29 Apr

United Therapeutics (UTHR) To Report Earnings Tomorrow: Here Is What To Expect

StockStory
·
29 Apr

Analysts Have Conflicting Sentiments on These Healthcare Companies: Ironwood Pharma (IRWD), AbbVie (ABBV) and Molecular Partners (MOLN)

TIPRANKS
·
29 Apr

BUZZ - S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT

Reuters
·
29 Apr

AbbVie Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
28 Apr

AbbVie price target raised to $227 from $220 at Raymond James

TIPRANKS
·
28 Apr

Raymond James Adjusts Price Target on AbbVie to $227 From $220, Maintains Outperform Rating

MT Newswires Live
·
28 Apr

BUZZ-Street View: AbbVie sees strong year ahead, minimizes US tariff concerns

Reuters
·
28 Apr

Should Investors Be Worried About Dividend King AbbVie?

Motley Fool
·
28 Apr

Abbvie : Morgan Stanley Raises Target Price to $250 From $241

THOMSON REUTERS
·
28 Apr

AbbVie Inc. (ABBV): Among Billionaire Ken Fisher’s Healthcare Stock Picks with Massive Upside Potential

Insider Monkey
·
28 Apr

AbbVie First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.
·
27 Apr

AbbVie Inc (ABBV) Q1 2025 Earnings Call Highlights: Strong Growth in Immunology and Neuroscience Drive Revenue Surge

GuruFocus
·
26 Apr